Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

While you're collecting healthy dividends, you'll also benefit from the price-to-earnings (P/E) ratio expanding when revenue ...

In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.46%. At the same time, the ...

Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep your expectations in check.

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer Inc. (NYSE: PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...